Basis: Trailing twelve months (TTM net income over the latest quarterly balance sheet). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on assets (ROA) high or low?
The return on assets (ROA) of -196.18% is 16% below its 4-year average of -169.68%, around the middle of its 4-year range (-459.80%–-49.37%).
41.35% above its 12-month average of -334.48%.
Reported quarterly return on assets; no daily interpolation. Q2 FY2026 (2026-06-30): -37.58%.
RETURN ON ASSETS (ROA)
-196.18%
RETURN ON ASSETS (ROA) AVG TTM
-334.48%
RETURN ON ASSETS (ROA) AVG 3Y
-197.38%
RETURN ON ASSETS (ROA) AVG 5Y
-169.68%
RETURN ON ASSETS (ROA) AVG 10Y
-244.65%
RETURN ON ASSETS (ROA) AVG 15Y
N/A
RETURN ON ASSETS (ROA) AVG 20Y
N/A
CURRENT VS TTM AVG
+41.35%
CURRENT VS 3Y AVG
+0.61%
CURRENT VS 5Y AVG
-15.62%
CURRENT VS 10Y AVG
+19.81%
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-26.34%
median of 496 covered companies
CURRENT VS SECTOR MEDIAN
-644.66%
vs the sector median at left
Artelo Biosciences, Inc.
Market Cap
$1.36M
Return on Assets (ROA)
-196.18%
TTM Avg
-334.48%
3Y Avg
-197.38%
5Y Avg
-169.68%
Market Cap
$1.37M
Return on Assets (ROA)
-96.27%
TTM Avg
-335.81%
3Y Avg
-263.87%
5Y Avg
-193.48%
Market Cap
$1.48M
Return on Assets (ROA)
-20.46%
TTM Avg
-67.47%
3Y Avg
-117.99%
5Y Avg
-101.96%
Market Cap
$1.49M
Return on Assets (ROA)
-36.88%
TTM Avg
-64.67%
3Y Avg
-76.84%
5Y Avg
-289.12%
Market Cap
$1.50M
Return on Assets (ROA)
-148.13%
TTM Avg
-399.46%
3Y Avg
-266.31%
5Y Avg
-266.31%
Market Cap
$1.54M
Return on Assets (ROA)
-111.51%
TTM Avg
-71.56%
3Y Avg
-64.13%
5Y Avg
-49.86%
Market Cap
$1.17M
Return on Assets (ROA)
-247.39%
TTM Avg
-97.35%
3Y Avg
-1378.80%
5Y Avg
-1078.71%
Market Cap
$1.17M
Return on Assets (ROA)
-64.99%
TTM Avg
-31.34%
3Y Avg
-98.36%
5Y Avg
-79.15%
Market Cap
$1.14M
Return on Assets (ROA)
-8.84%
TTM Avg
-4.56%
3Y Avg
8.88%
5Y Avg
8.88%
| NAME | MARKET CAP | RETURN ON ASSETS (ROA) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Artelo Biosciences, Inc. (ARTL) | $1.36M | -196.18% | -334.48% | -197.38% | -169.68% |
| Genprex, Inc. (GNPX)vs › | $1.37M | -96.27% | -335.81% | -263.87% | -193.48% |
| INVO Fertility, Inc. (IVF)vs › | $1.48M | -20.46% | -67.47% | -117.99% | -101.96% |
| PMGC Holdings Inc. (ELAB)vs › | $1.49M | -36.88% | -64.67% | -76.84% | -289.12% |
| Lakewood-Amedex Biotherapeutics, Inc. (LABT)vs › | $1.50M | -148.13% | -399.46% | -266.31% | -266.31% |
| Curis, Inc. (CRIS)vs › | $1.54M | -111.51% | -71.56% | -64.13% | -49.86% |
| Jupiter Neurosciences, Inc. (JUNS)vs › | $1.17M | -247.39% | -97.35% | -1378.80% | -1078.71% |
| IM Cannabis Corp. (IMCC)vs › | $1.17M | -64.99% | -31.34% | -98.36% | -79.15% |
| Cellyan Biotechnology Co., Ltd (HKPD)vs › | $1.14M | -8.84% | -4.56% | 8.88% | 8.88% |
| Clearmind Medicine Inc. (CMND)vs › | $1.11M | -44.32% | -57.72% | -286.30% | -215.47% |
ROA
-196.2%
ROE
-253.6%
ROA = Net Income / Total Assets
Return on assets measures how efficiently a company generates profit from its total assets.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON ASSETS (ROA) |
|---|---|
| 2025-12-31 | -459.80% |
| 2024-12-31 | -209.15% |
| 2023-12-31 | -71.22% |
| 2022-12-31 | -49.37% |
| 2021-08-31 | -58.86% |
| 2020-08-31 | -106.38% |
| 2019-08-31 | -33.51% |
| 2018-08-31 | -590.30% |
| 2017-08-31 | -40.90% |
| 2016-08-31 | -827.02% |
| 2015-08-31 | -89.50% |
| 2014-08-31 | -103.65% |
